Neurolixis Inc. has been awarded a 1M$ research grant by the British charity, Parkinson's UK to advance development of NLX-112, a promising Phase 2-ready candidate for treatment of levodopa-induced dyskinesia (LID). NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist with considerable potential for treatment of this indication.

Read the full announcement on the Parkinson's UK web site.

Image result for parkinson uk

Newsletter

Veuillez activer le javascript sur cette page pour pouvoir valider le formulaire

Follow Neurolixis on: